• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吗啉类化合物在中枢神经系统药物研发中的应用

Occurrence of Morpholine in Central Nervous System Drug Discovery.

机构信息

Department of Chemistry "Ugo Schiff", University of Florence, via della Lastruccia 13, 50019 Sesto Fiorentino, Florence, Italy.

出版信息

ACS Chem Neurosci. 2021 Feb 3;12(3):378-390. doi: 10.1021/acschemneuro.0c00729. Epub 2021 Jan 18.

DOI:10.1021/acschemneuro.0c00729
PMID:33459557
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7877733/
Abstract

Developing drugs for the central nervous system (CNS) requires fine chemical modifications, as a strict balance between size and lipophilicity is necessary to improve the permeability through the blood-brain barrier (BBB). In this context, morpholine and its analogues represent valuable heterocycles, due to their conformational and physicochemical properties. In fact, the presence of a weak basic nitrogen atom and of an oxygen atom at the opposite position provides a peculiar p value and a flexible conformation to the ring, thus allowing it to take part in several lipophilic-hydrophilic interactions, and to improve blood solubility and brain permeability of the overall structure. In CNS-active compounds, morpholines are used (1) to enhance the potency through molecular interactions, (2) to act as a scaffold directing the appendages in the correct position, and (3) to modulate pharmacokinetic/pharmacodynamic (PK/PD) properties. In this perspective, selected morpholine-containing CNS drug candidates are discussed to reveal the active pharmacophores accountable for the (1) modulation of receptors involved in mood disorders and pain, (2) bioactivity toward enzymes and receptors responsible for neurodegenerative diseases, and (3) inhibition of enzymes involved in the pathology of CNS tumors. The medicinal chemistry/pharmacological activity of morpholine derivatives is discussed, in the effort to highlight the importance of morpholine ring interactions in the active site of different targets, particularly reporting binding features retrieved from PDB data, when available.

摘要

开发治疗中枢神经系统 (CNS) 的药物需要进行精细的化学修饰,因为必须在大小和亲脂性之间取得严格的平衡,以提高穿过血脑屏障 (BBB) 的通透性。在这种情况下,由于具有构象和物理化学性质,吗啡啉及其类似物代表了有价值的杂环。事实上,由于弱碱性氮原子和相反位置上的氧原子的存在,使得环具有独特的 p 值和灵活的构象,从而使其能够参与多种亲脂-亲水相互作用,并提高整体结构的血液溶解度和脑通透性。在 CNS 活性化合物中,吗啡啉被用于 (1) 通过分子相互作用增强效力,(2) 作为引导附属物进入正确位置的支架,以及 (3) 调节药代动力学/药效学 (PK/PD) 性质。从这个角度来看,讨论了选定的含有吗啡啉的 CNS 候选药物,以揭示负责 (1) 调节与情绪障碍和疼痛相关的受体,(2) 对负责神经退行性疾病的酶和受体的生物活性,以及 (3) 抑制 CNS 肿瘤病理学相关酶的药效团。讨论了吗啡啉衍生物的药物化学/药理活性,以强调吗啡啉环相互作用在不同靶点的活性部位中的重要性,特别是在可用时报告从 PDB 数据中检索到的结合特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/df15c56aad77/cn0c00729_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/a228c52c9b5b/cn0c00729_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/ae0114b4b8c6/cn0c00729_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/a255be2d572c/cn0c00729_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/3b5aacb8cea2/cn0c00729_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/279bf4cbe4bf/cn0c00729_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/842baa52bf8d/cn0c00729_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/c93e492554b1/cn0c00729_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/43eda1c0d213/cn0c00729_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/d4314588bdb8/cn0c00729_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/828ee1307054/cn0c00729_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/07405d98ba00/cn0c00729_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/ea320bf22520/cn0c00729_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/a795f8ced058/cn0c00729_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/d50d42d17fe3/cn0c00729_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/a699be8baafe/cn0c00729_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/3fff5ba6bdb7/cn0c00729_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/4b49c1a0a52d/cn0c00729_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/df15c56aad77/cn0c00729_0018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/a228c52c9b5b/cn0c00729_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/ae0114b4b8c6/cn0c00729_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/a255be2d572c/cn0c00729_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/3b5aacb8cea2/cn0c00729_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/279bf4cbe4bf/cn0c00729_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/842baa52bf8d/cn0c00729_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/c93e492554b1/cn0c00729_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/43eda1c0d213/cn0c00729_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/d4314588bdb8/cn0c00729_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/828ee1307054/cn0c00729_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/07405d98ba00/cn0c00729_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/ea320bf22520/cn0c00729_0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/a795f8ced058/cn0c00729_0013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/d50d42d17fe3/cn0c00729_0014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/a699be8baafe/cn0c00729_0015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/3fff5ba6bdb7/cn0c00729_0016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/4b49c1a0a52d/cn0c00729_0017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d03/7877733/df15c56aad77/cn0c00729_0018.jpg

相似文献

1
Occurrence of Morpholine in Central Nervous System Drug Discovery.吗啉类化合物在中枢神经系统药物研发中的应用
ACS Chem Neurosci. 2021 Feb 3;12(3):378-390. doi: 10.1021/acschemneuro.0c00729. Epub 2021 Jan 18.
2
Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR).吗啡啉作为药物化学中无处不在的药效团:对结构-活性关系(SAR)的深入洞察。
Bioorg Chem. 2020 Mar;96:103578. doi: 10.1016/j.bioorg.2020.103578. Epub 2020 Jan 11.
3
Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules.吗啡啉作为一种特权结构:吗啡啉含生物活性分子的药物化学和药理学活性综述。
Med Res Rev. 2020 Mar;40(2):709-752. doi: 10.1002/med.21634. Epub 2019 Sep 12.
4
Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.超越规则:中枢神经系统多参数优化 (CNS MPO) 方法的开发,以实现类似药物特性的一致性。
ACS Chem Neurosci. 2010 Jun 16;1(6):435-49. doi: 10.1021/cn100008c. Epub 2010 Mar 25.
5
Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.整合计算机模拟和体外实验方法以预测药物进入中枢神经系统的可及性
Mol Pharm. 2016 May 2;13(5):1540-50. doi: 10.1021/acs.molpharmaceut.6b00031. Epub 2016 Apr 4.
6
A method to predict different mechanisms for blood-brain barrier permeability of CNS activity compounds in Chinese herbs using support vector machine.一种使用支持向量机预测中药中中枢神经系统活性化合物血脑屏障通透性不同机制的方法。
J Bioinform Comput Biol. 2016 Feb;14(1):1650005. doi: 10.1142/S0219720016500050. Epub 2015 Oct 27.
7
Explaining Blood-Brain Barrier Permeability of Small Molecules by Integrated Analysis of Different Transport Mechanisms.综合分析不同转运机制解释小分子的血脑屏障通透性。
J Med Chem. 2023 Jun 8;66(11):7253-7267. doi: 10.1021/acs.jmedchem.2c01824. Epub 2023 May 22.
8
Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.血脑屏障转运的转化研究及药物对中枢神经系统的影响:从发现到临床应用
Clin Pharmacol Ther. 2015 Apr;97(4):380-94. doi: 10.1002/cpt.76. Epub 2015 Feb 20.
9
Practical approaches to evaluating and optimizing brain exposure in early drug discovery.在早期药物发现中评估和优化脑暴露的实用方法。
Eur J Med Chem. 2019 Nov 15;182:111643. doi: 10.1016/j.ejmech.2019.111643. Epub 2019 Aug 23.
10
Medicinal chemical properties of successful central nervous system drugs.成功的中枢神经系统药物的药用化学性质。
NeuroRx. 2005 Oct;2(4):541-53. doi: 10.1602/neurorx.2.4.541.

引用本文的文献

1
Chronic dimethomorph exposure induced behaviors abnormalities and cognitive performance alterations in adult zebrafish ().长期暴露于烯酰吗啉会导致成年斑马鱼出现行为异常和认知能力改变。
Toxicol Rep. 2025 Feb 25;14:101977. doi: 10.1016/j.toxrep.2025.101977. eCollection 2025 Jun.
2
Microwave-Assisted Synthesis of Morpholine-Based Chalcones as Reversible MAO-A Inhibitors in the Management of Mental Depression.微波辅助合成基于吗啉的查尔酮作为治疗精神抑郁症的可逆性单胺氧化酶-A抑制剂
Pharmaceuticals (Basel). 2025 Feb 23;18(3):309. doi: 10.3390/ph18030309.
3
Short Scalable Route to Bis-morpholine Spiroacetals and Oxazepane Analogues: Useful 3D-Scaffolds for Compound Library Assembly.

本文引用的文献

1
Radiosynthesis and evaluation of 4-(6-[F]Fluoro-4-(5-isopropoxy-1-indazol-3-yl)pyridin-2-yl)morpholine as a novel radiotracer candidate targeting leucine-rich repeat kinase 2.4-(6-[F]氟-4-(5-异丙氧基-1-吲唑-3-基)吡啶-2-基)吗啉作为靶向富含亮氨酸重复激酶2的新型放射性示踪剂候选物的放射性合成及评价
RSC Med Chem. 2020 May 19;11(6):676-684. doi: 10.1039/c9md00590k. eCollection 2020 Jun 1.
2
Indole compounds with -ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation.具有 - 乙基吗啉部分的吲哚化合物作为CB2受体激动剂用于疼痛的抗炎治疗:合成与生物学评价
Medchemcomm. 2019 Sep 17;10(11):1935-1947. doi: 10.1039/c9md00173e. eCollection 2019 Nov 1.
3
双吗啉螺缩醛和氧杂氮杂环庚烷类似物的短程可扩展合成路线:用于化合物库组装的有用三维支架
J Org Chem. 2025 Feb 21;90(7):2652-2661. doi: 10.1021/acs.joc.4c02690. Epub 2025 Feb 10.
4
Transparent Machine Learning Model to Understand Drug Permeability through the Blood-Brain Barrier.用于理解药物通过血脑屏障渗透性的透明机器学习模型。
J Chem Inf Model. 2024 Dec 9;64(23):8718-8728. doi: 10.1021/acs.jcim.4c01217. Epub 2024 Nov 18.
5
Synthesis and Characterization of Copper(II) and Nickel(II) Complexes with 3-(Morpholin-4-yl)propane-2,3-dione 4-Allylthiosemicarbazone Exploring the Antibacterial, Antifungal and Antiradical Properties.3-(吗啉-4-基)丙烷-2,3-二酮 4-烯丙基硫代缩氨脲合铜(II)和镍(II)配合物的合成与表征:抗菌、抗真菌和抗自由基性能的研究。
Molecules. 2024 Aug 17;29(16):3903. doi: 10.3390/molecules29163903.
6
C-Alkylation of Imidazo[1,2-a]pyridines via Three-Component Aza-Friedel-Crafts Reaction Catalyzed by Y(OTf).通过Y(OTf)催化的三组分氮杂傅克反应实现咪唑并[1,2-a]吡啶的C-烷基化反应
Molecules. 2024 Jul 24;29(15):3463. doi: 10.3390/molecules29153463.
7
Morpholine-modified Ru-based agents with multiple antibacterial mechanisms as metalloantibiotic candidates against infection.具有多种抗菌机制的吗啉修饰钌基制剂作为抗感染金属抗生素候选物。
RSC Adv. 2024 Jun 24;14(28):20130-20144. doi: 10.1039/d4ra02667e. eCollection 2024 Jun 18.
8
Expanding Complex Morpholines Using Systematic Chemical Diversity.利用系统化学多样性拓展复杂吗啡啉。
Org Lett. 2024 May 3;26(17):3493-3497. doi: 10.1021/acs.orglett.4c00528. Epub 2024 Mar 20.
9
Cannabidiol-Based Prodrugs: Synthesis and Bioevaluation.基于大麻二酚的前药:合成与生物评价
ACS Med Chem Lett. 2024 Jan 16;15(2):221-229. doi: 10.1021/acsmedchemlett.3c00461. eCollection 2024 Feb 8.
10
Discovery of imidazo[1,2-]pyridazine-containing TAK1 kinase inhibitors with excellent activities against multiple myeloma.发现含咪唑并[1,2 - ]哒嗪的TAK1激酶抑制剂,对多发性骨髓瘤具有优异活性。
RSC Med Chem. 2023 Nov 28;15(1):178-192. doi: 10.1039/d3md00415e. eCollection 2024 Jan 25.
Synthesis of morpholine derivatives using the Castagnoli-Cushman reaction as BACE1 inhibitors: Unexpected binding activity of cyclic thioamides.
使用 Castagnoli-Cushman 反应作为 BACE1 抑制剂合成吗啉衍生物:环状硫代酰胺的意外结合活性。
Bioorg Med Chem Lett. 2020 Jul 1;30(13):127211. doi: 10.1016/j.bmcl.2020.127211. Epub 2020 Apr 24.
4
Design and Synthesis of Backbone-Fused, Conformationally Constrained Morpholine-Proline Chimeras.设计并合成骨架融合的、构象受限的吗啉-脯氨酸嵌合体。
J Org Chem. 2020 Mar 20;85(6):4237-4247. doi: 10.1021/acs.joc.9b03413. Epub 2020 Mar 5.
5
Synthesis and biological evaluation of novel pyrimidine-5-carbonitriles featuring morpholine moiety as antitumor agents.新型含吗啉基嘧啶-5-甲腈类化合物的合成及抗肿瘤活性评价。
Future Med Chem. 2020 Mar;12(5):403-421. doi: 10.4155/fmc-2019-0146. Epub 2020 Feb 6.
6
Morpholine As a Scaffold in Medicinal Chemistry: An Update on Synthetic Strategies.吗啡啉作为药物化学中的一种骨架:合成策略的最新进展。
ChemMedChem. 2020 Mar 5;15(5):392-403. doi: 10.1002/cmdc.201900682. Epub 2020 Feb 12.
7
Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR).吗啡啉作为药物化学中无处不在的药效团:对结构-活性关系(SAR)的深入洞察。
Bioorg Chem. 2020 Mar;96:103578. doi: 10.1016/j.bioorg.2020.103578. Epub 2020 Jan 11.
8
Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders.发现一种穿透血脑屏障的机械靶标雷帕霉素(mTOR)的 ATP 竞争性抑制剂,用于中枢神经系统疾病。
J Med Chem. 2020 Feb 13;63(3):1068-1083. doi: 10.1021/acs.jmedchem.9b01398. Epub 2020 Jan 31.
9
Dementia in long-term Parkinson's disease patients: a multicentre retrospective study.长期帕金森病患者的痴呆:一项多中心回顾性研究。
NPJ Parkinsons Dis. 2020 Jan 7;6:2. doi: 10.1038/s41531-019-0106-4. eCollection 2020.
10
Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules.吗啡啉作为一种特权结构:吗啡啉含生物活性分子的药物化学和药理学活性综述。
Med Res Rev. 2020 Mar;40(2):709-752. doi: 10.1002/med.21634. Epub 2019 Sep 12.